- Post-Hoc: China deals are pharma’s new tax inversionsAbout a decade ago, when I had just started covering pharma, one of the biggest stories was tax inversions. For those who don’t remember, tax inversions were a form of M&A in which a US ...Endpoints · 27d ago↗ source
- Ipsen to buy blood cancer company Kartos Therapeutics for $450M upfrontIpsen is earmarking up to $1.75 billion to take Kartos Therapeutics and its MDM2 protein-targeting drug candidate that it in-licensed from Amgen back in 2016. Ipsen will pay $450 million upfront ...Endpoints · 27d ago↗ source
- De-Risking a Rare Disease Launch Starts with PrecisionWhy traditional models fall short in rare disease commercialization—and what works instead.Fierce Biotech · 1mo ago↗ source